ADAP Advocacy has released a retrospective white paper examining the 340B Drug Pricing Program, arguing that the program has veered from its original legislative intent and that reform is necessary to better serve patients. The paper, titled "340B Program: The Glue That Should Hold Our Healthcare System Together," calls for a robust program as a major part of the healthcare system but outlines how its growth has outpaced the ability to clearly see how it is helping patients.
The 340B Program is now the second-largest federal prescription drug program in the United States, behind Medicare Part D. According to the white paper, the program has prioritized provider interests over patient interests, leading to a need for greater transparency and accountability. Brandon M. Macsata, CEO of ADAP Advocacy, stated: "There is an ongoing effort to push for greater transparency across multiple layers of this country's fragmented healthcare system, including hospitals' patient billing practices and pharmacy benefit managers' spread pricing policies. The 340B Program shouldn't be excluded from this broader effort, especially since the ultimate goal is improved program efficiency, leading to greater access to care and treatment for low-income patients."
The white paper highlights three central questions driving the calls for reform: if 340B is designed to expand access and reduce financial burden, why are patients increasingly unable to afford care? Why is 340B not adequately addressing this problem? And why is it failing to meet the needs of the uninsured and underinsured, the very persons it was designed to serve?
The paper reads, in part: "What started as a support mechanism has grown into something larger, both in terms of dollars and in the depth of the program's integration into the financial aspects of the American healthcare system. For that reason, a healthcare program of this size, magnitude, and importance cannot be entrusted to good faith alone; rather, improved accountability and transparency guardrails are needed to ensure its success and ultimately its intended beneficiaries: patients."
The white paper is available online at https://www.adapadvocacy.org/policycenter/340b. ADAP Advocacy works with advocates, community, health care, government, patients, pharmaceutical companies and other stakeholders to raise awareness and foster greater community collaboration. The retrospective analysis serves as a critical examination of a program that has become deeply integrated into the financial aspects of American healthcare, and the implications for business and technology leaders are significant: without reform, the program may continue to fall short of its mission, potentially affecting millions of low-income patients who rely on it for access to life-saving medications.
